Diabetes Drugs Market- Global Industry Analysis and Forecast 2027: By Treatment Type, Disease Type, Distribution Channel and Region.

Diabetes Drugs Market is expected to reach US$ 99.12 Bn. at a CAGR of 4.50% during the forecast period 2027. Diabetes Drugs Market To know about the Research Methodology :- Request Free Sample Report

Diabetes Drugs Market Overview:

Diabetes drugs are the medicines which are used for the treatment of diabetes mellitus type 1 and type 2, and it maintains the regular blood glucose level of the body. There are several classes of drugs that are available to treat the diabetes and these drugs can be administered via Gestational Diabetes, Impaired Glucose Tolerance and Impaired Fasting Glycaemia route or intravenous and subcutaneous routes. The scope of the report includes a detailed study of global and regional markets for Diabetes Drugs with the reasons given for variants in the growth of the industry in certain regions.

Diabetes Drugs Market Dynamics:

Increasing incidence of diabetes, particularly type 2 diabetes, and the growing demand for effective drug therapies for the treatment of diabetes are the factors expected to increase the diabetes drugs market throughout the forecast period. Recently, Centers for Disease Control and Prevention (CDC) reported that, around million people in the U.S. were suffering from diabetes and among that  million people were diagnosed with diabetes, and the remaining were still undiagnosed. Similarly, according to International Diabetes Federation, it was estimated that  million adult population were suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach  million by 2027. The approvals of new drugs like Canagliflozin and dapagliflozin for the treatment of diabetes, would generate several opportunities for new as well as existing players in the diabetes drugs market. The growing diabetic population, technological improvements and the raising adoption rate in emerging regions are the key factors, which would drive the growth of diabetes drugs market over forecast period. Similarly, increase in obesity, rising adoption of a sedentary lifestyle and upsurge in consumption of unhealthy diet are expected to enhance the incidence of diabetes which are expected to boost the market throughout the forecast period. Increasing geriatric population across the world and rising incidence and prevalence of diabetes such as Type 2 diabetes and Type 1 diabetes are some of the factors expected to drive the growth of Diabetes drugs market during the forecast period. While, two major factors that restrain the market growth are stringent regulatory environment and time consuming approval process. The report on Diabetes Drugs market covers segments such as By Treatment Type, Disease Type, Distribution Channel and Region. The Treatment Type segment includes Glucagon-like peptide-1 (GLP-1) agonist, Dipeptidyl-peptidase-4 (DPP-4) inhibitors, Sodium glucose co-transporter 2 (SGLT2) inhibitors, Insulin, Exenatide, Liragultide, Pramlintide, Biguanides, Sulfonylureas, Meglitinides and D-Phenylalanine Derivatives, Thiazolidinediones, DPP-4 Inhibitors, Alpha-glucosidase Inhibitors, Bile Acid Sequestrants, and Others (Combination Pills). Among the Treatment Type, Insulin is accounted for the largest XX% market share in the Diabetes Drugs market, due to its high price, and need & demand for insulin. Insulin is anticipated to lead the market in the forecast period, due to the increasing geriatric population and high per capita income. SGLT2 is expected to grow throughout the forecast period due to patents and exclusivity held for the drugs of this segment by the key players. The others segment comprises the combination drugs and other drug classes are expected to grow throughout the forecast period. The Glucagon-like peptide-1 (GLP-1) agonist is expected to grow throughout the forecast period because of increasing incidence of diabetes all over the globe. Dipeptidyl-peptidase-4 (DPP-4) inhibitors held second large market share in 2021, nevertheless, the segment is expected to fall in the growth rate throughout the forecast period owing to patent and exclusivity expiry.

Diabetes Drugs Market Segment:

The Disease Type segment is further sub-segmented into Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Impaired Glucose Tolerance and Impaired Fasting Glycaemia. Type 2 diabetes has accounted for greatest market share owing to growing disposable income and increasing occurrence of obesity. Raising physical inactivity generated demand for the diabetes drugs. Type 1 diabetes held the second large market share in 2021 due to raising environmental damage all over the globe that is supporting to the increasing incidence of type 1 diabetes. Gestational diabetes and impaired glucose tolerance and impaired fasting glycaemia are expected to grow throughout the forecast period, due to the high occurrence of diabetes in the relatives and heredity reason. Based on Distribution Channel, the Diabetes Drugs market is sub-segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital Pharmacies occupied highest market share in 2021, due to the convenience of trained & qualified personnel and promising reimbursement structure. The online Pharmacies is projected to demonstration highest CAGR in the forecast period, which is recognized to the technological adaptation and acceptance of online Pharmacies by population. The retail Pharmacies demonstrated the reasonable market share in 2021 due to increasing geriatric population & developments in the healthcare amenities in emerging countries are estimated to drive the popularity of retail Pharmacies throughout the forecast period. Nevertheless, indefinite reimbursement consequences across the globe are indorsed to hamper the diabetes drugs market to some magnitude throughout the forecast period. Based on regional segment, the Diabetes Drugs market is sub-segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America leads the diabetes drug market due to large diabetic patient population. Additionally, raising number of obesity in people, fluctuating lifestyle and growing healthcare expenditure have boosted the growth of the diabetes drug market in North America. Moreover, growing awareness between the people about different monitoring techniques, increasing awareness and well-developed technology have also promoted to the growth of diabetes drug market. Europe is register for the second largest diabetes drug market, and then Asia Pacific hold third position in the market. Massive smoking population, availability of funds for research, and government provision for research & development will drive the diabetes drug market in Europe. Asia Pacific is the fastest growing region for the diabetes drug market owing to the existence of a huge patient population, constantly emerging economies, and raising need for the enhanced treatment. Instead of this, the Middle East & Africa has the least share in the diabetes drug market due to presence of poor economy particularly in Africa region. Middle East holds the key share in the Middle East & Africa diabetes drug market due to well-developed healthcare area and huge healthcare expenditure. Key players operating in the Diabetes Drugs market are Nordisk A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim GmbH, Sanofi, Bayer AG, Johnson & Johnson, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Abbott laboratories, Biocon ltd, Bristol-Myers Squibb, Dr. Reddy's laboratories ltd., Glaxosmithkline, Lupin ltd, Piramal healthcare ltd., Ranbaxy laboratories ltd., AstraZeneca, Sunpharma, Pfizer, Daiichi Sankyo, Akros Pharma, Amgen, Adocia, and Peptron. GlaxoSmithKline plc. received US$ 6.6 Mn from Tres Cantos Open Lab Foundation (TCOLF) for innovation and research on diseases impacting the developing world in September 2018. Additionally, Pfizer, Inc. partnered with GlaxoSmithKline plc. to form a joint venture to create the world’s largest over-the-counter (OTC) business, in August 2018. The companies functioning in the market are concentrating on R&D investments and fund raising activities to drive clinical trials that lead to robust product pipeline. As detection rate and market perception withstand to expand, there are anticipations for market growth during forecast period. Furthermore, innovative product sanctions in the market will further drive the market growth. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Diabetes Drugs market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by Product, price, financial position, Product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Diabetes Drugs market.

Diabetes Drugs Market Scope: Inquire before buying

Diabetes Drugs Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US $ 76.11 Bn.
Forecast Period 2022 to 2027 CAGR: 4.50% Market Size in 2027: US $ 99.12 Bn.
Segments Covered: by Treatment Type • Glucagon-like peptide-1 (GLP-1) agonist • Dipeptidyl-peptidase-4 (DPP-4) inhibitors • Sodium glucose co-transporter 2 (SGLT2) inhibitors • Insulin • Exenatide • Liragultide • Pramlintide • Biguanides • Sulfonylureas • Meglitinides and D-Phenylalanine Derivatives • Thiazolidinediones • DPP-4 Inhibitors • Alpha-glucosidase Inhibitors • Bile Acid Sequestrants • Others (Combination Pills)
by Disease Type • Type 1 Diabetes • Type 2 Diabetes • Gestational Diabetes • Impaired Glucose Tolerance and Impaired Fasting Glycaemia
by Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies

Diabetes Drugs Market, by Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Diabetes Drugs Market Key Players:

• Nordisk A/S • Merck & Co., Inc. • Novartis AG • Boehringer Ingelheim GmbH • Sanofi • Bayer AG • Johnson & Johnson • Eli Lilly and Company • Takeda Pharmaceutical Company Limited. • Abbott laboratories • Biocon ltd. • Bristol-Myers Squibb • Dr. Reddy's laboratories ltd. • Glaxosmithkline • Lupin ltd. • Piramal healthcare ltd. • Ranbaxy laboratories ltd. • AstraZeneca • Sunpharma • Pfizer • Daiichi Sankyo • Akros Pharma • Amgen • Adocia • Peptron Frequently Asked Questions: 1. Which region has the largest share in Global Diabetes Drugs Market? Ans: Asia Pacific region held the highest share in 2021. 2. What is the growth rate of Global Diabetes Drugs Market? Ans: The Global Diabetes Drugs Market is expected to grow at a CAGR of 4.50% during forecast period 2022-2027. 3. What is scope of the Global Diabetes Drugs market report? Ans: Global Diabetes Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Diabetes Drugs market? Ans: The important key players in the Global Diabetes Drugs Market are – Nordisk A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim GmbH, Sanofi, Bayer AG, Johnson & Johnson, Eli Lilly and Company, Takeda Pharmaceutical Company Limited., Abbott laboratories, Biocon ltd., Bristol-Myers Squibb, Dr. Reddy's laboratories ltd., Glaxosmithkline, Lupin ltd., Piramal healthcare ltd., Ranbaxy laboratories ltd., AstraZeneca, Sunpharma, Pfizer, Daiichi Sankyo, Akros Pharma, Amgen, Adocia, and Peptron 5. What is the study period of this market? Ans: The Global Diabetes Drugs Market is studied from 2021 to 2027.
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Diabetes Drugs Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Diabetes Drugs Market Analysis and Forecast 6.1. Global Diabetes Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Diabetes Drugs Market Analysis and Forecast, By Treatment Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Diabetes Drugs Market Value Share Analysis, By Treatment Type 7.4. Global Diabetes Drugs Market Size (US$ Mn) Forecast, By Treatment Type 7.5. Global Diabetes Drugs Market Analysis, By Treatment Type 7.6. Global Diabetes Drugs Market Attractiveness Analysis, By Treatment Type 8. Diabetes Drugs Market Analysis and Forecast, By Disease Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Diabetes Drugs Market Value Share Analysis, By Disease Type 8.4. Global Diabetes Drugs Market Size (US$ Mn) Forecast, By Disease Type 8.5. Global Diabetes Drugs Market Analysis, By Disease Type 8.6. Global Diabetes Drugs Market Attractiveness Analysis, By Disease Type 9. Diabetes Drugs Market Analysis and Forecast, By Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Diabetes Drugs Market Value Share Analysis, By Distribution Channel 9.4. Global Diabetes Drugs Market Size (US$ Mn) Forecast, By Distribution Channel 9.5. Global Diabetes Drugs Market Analysis, By Distribution Channel 9.6. Global Diabetes Drugs Market Attractiveness Analysis, By Distribution Channel 10. Diabetes Drugs Market Analysis, by Region 10.1. Global Diabetes Drugs Market Value Share Analysis, by Region 10.2. Global Diabetes Drugs Market Size (US$ Mn) Forecast, by Region 10.3. Global Diabetes Drugs Market Attractiveness Analysis, by Region 11. North America Diabetes Drugs Market Analysis 11.1. Key Findings 11.2. North America Diabetes Drugs Market Overview 11.3. North America Diabetes Drugs Market Value Share Analysis, By Treatment Type 11.4. North America Diabetes Drugs Market Forecast, By Treatment Type 11.4.1. Glucagon-like peptide-1 (GLP-1) agonist 11.4.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 11.4.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 11.4.4. Insulin 11.4.5. Exenatide 11.4.6. Liragultide 11.4.7. Pramlintide 11.4.8. Biguanides 11.4.9. Sulfonylureas 11.4.10. Meglitinides and D-Phenylalanine Derivatives 11.4.11. Thiazolidinediones 11.4.12. DPP-4 Inhibitors 11.4.13. Alpha-glucosidase Inhibitors 11.4.14. Bile Acid Sequestrants 11.4.15. Others (Combination Pills) 11.5. North America Diabetes Drugs Market Value Share Analysis, By Disease Type 11.6. North America Diabetes Drugs Market Forecast, By Disease Type 11.6.1. Type 1 Diabetes 11.6.2. Type 2 Diabetes 11.6.3. Gestational Diabetes 11.6.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 11.7. North America Diabetes Drugs Market Value Share Analysis, By Distribution Channel 11.8. North America Diabetes Drugs Market Forecast, By Distribution Channel 11.8.1. Hospital Pharmacies 11.8.2. Retail Pharmacies 11.8.3. Online Pharmacies 11.9. North America Diabetes Drugs Market Value Share Analysis, by Country 11.10. North America Diabetes Drugs Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Diabetes Drugs Market Analysis, by Country 11.12. U.S. Diabetes Drugs Market Forecast, By Treatment Type 11.12.1. Glucagon-like peptide-1 (GLP-1) agonist 11.12.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 11.12.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 11.12.4. Insulin 11.12.5. Exenatide 11.12.6. Liragultide 11.12.7. Pramlintide 11.12.8. Biguanides 11.12.9. Sulfonylureas 11.12.10. Meglitinides and D-Phenylalanine Derivatives 11.12.11. Thiazolidinediones 11.12.12. DPP-4 Inhibitors 11.12.13. Alpha-glucosidase Inhibitors 11.12.14. Bile Acid Sequestrants 11.12.15. Others (Combination Pills) 11.13. U.S. Diabetes Drugs Market Forecast, By Disease Type 11.13.1. Type 1 Diabetes 11.13.2. Type 2 Diabetes 11.13.3. Gestational Diabetes 11.13.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 11.14. U.S. Diabetes Drugs Market Forecast, By Distribution Channel 11.14.1. Hospital Pharmacies 11.14.2. Retail Pharmacies 11.14.3. Online Pharmacies 11.15. Canada Diabetes Drugs Market Forecast, By Treatment Type 11.15.1. Glucagon-like peptide-1 (GLP-1) agonist 11.15.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 11.15.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 11.15.4. Insulin 11.15.5. Exenatide 11.15.6. Liragultide 11.15.7. Pramlintide 11.15.8. Biguanides 11.15.9. Sulfonylureas 11.15.10. Meglitinides and D-Phenylalanine Derivatives 11.15.11. Thiazolidinediones 11.15.12. DPP-4 Inhibitors 11.15.13. Alpha-glucosidase Inhibitors 11.15.14. Bile Acid Sequestrants 11.15.15. Others (Combination Pills) 11.16. Canada Diabetes Drugs Market Forecast, By Disease Type 11.16.1. Type 1 Diabetes 11.16.2. Type 2 Diabetes 11.16.3. Gestational Diabetes 11.16.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 11.17. Canada Diabetes Drugs Market Forecast, By Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Retail Pharmacies 11.17.3. Online Pharmacies 11.18. North America Diabetes Drugs Market Attractiveness Analysis 11.18.1. By Treatment Type 11.18.2. By Disease Type 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Diabetes Drugs Market Analysis 12.1. Key Findings 12.2. Europe Diabetes Drugs Market Overview 12.3. Europe Diabetes Drugs Market Value Share Analysis, By Treatment Type 12.4. Europe Diabetes Drugs Market Forecast, By Treatment Type 12.4.1. Glucagon-like peptide-1 (GLP-1) agonist 12.4.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 12.4.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 12.4.4. Insulin 12.4.5. Exenatide 12.4.6. Liragultide 12.4.7. Pramlintide 12.4.8. Biguanides 12.4.9. Sulfonylureas 12.4.10. Meglitinides and D-Phenylalanine Derivatives 12.4.11. Thiazolidinediones 12.4.12. DPP-4 Inhibitors 12.4.13. Alpha-glucosidase Inhibitors 12.4.14. Bile Acid Sequestrants 12.4.15. Others (Combination Pills) 12.5. Europe Diabetes Drugs Market Value Share Analysis, By Disease Type 12.6. Europe Diabetes Drugs Market Forecast, By Disease Type 12.6.1. Type 1 Diabetes 12.6.2. Type 2 Diabetes 12.6.3. Gestational Diabetes 12.6.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 12.7. Europe Diabetes Drugs Market Value Share Analysis, By Distribution Channel 12.8. Europe Diabetes Drugs Market Forecast, By Distribution Channel 12.8.1. Hospital Pharmacies 12.8.2. Retail Pharmacies 12.8.3. Online Pharmacies 12.9. Europe Diabetes Drugs Market Value Share Analysis, by Country 12.10. Europe Diabetes Drugs Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Diabetes Drugs Market Analysis, by Country 12.12. Germany Diabetes Drugs Market Forecast, By Treatment Type 12.12.1. Glucagon-like peptide-1 (GLP-1) agonist 12.12.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 12.12.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 12.12.4. Insulin 12.12.5. Exenatide 12.12.6. Liragultide 12.12.7. Pramlintide 12.12.8. Biguanides 12.12.9. Sulfonylureas 12.12.10. Meglitinides and D-Phenylalanine Derivatives 12.12.11. Thiazolidinediones 12.12.12. DPP-4 Inhibitors 12.12.13. Alpha-glucosidase Inhibitors 12.12.14. Bile Acid Sequestrants 12.12.15. Others (Combination Pills) 12.13. Germany Diabetes Drugs Market Forecast, By Disease Type 12.13.1. Type 1 Diabetes 12.13.2. Type 2 Diabetes 12.13.3. Gestational Diabetes 12.13.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 12.14. Germany Diabetes Drugs Market Forecast, By Distribution Channel 12.14.1. Hospital Pharmacies 12.14.2. Retail Pharmacies 12.14.3. Online Pharmacies 12.15. U.K. Diabetes Drugs Market Forecast, By Treatment Type 12.15.1. Glucagon-like peptide-1 (GLP-1) agonist 12.15.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 12.15.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 12.15.4. Insulin 12.15.5. Exenatide 12.15.6. Liragultide 12.15.7. Pramlintide 12.15.8. Biguanides 12.15.9. Sulfonylureas 12.15.10. Meglitinides and D-Phenylalanine Derivatives 12.15.11. Thiazolidinediones 12.15.12. DPP-4 Inhibitors 12.15.13. Alpha-glucosidase Inhibitors 12.15.14. Bile Acid Sequestrants 12.15.15. Others (Combination Pills) 12.16. U.K. Diabetes Drugs Market Forecast, By Disease Type 12.16.1. Type 1 Diabetes 12.16.2. Type 2 Diabetes 12.16.3. Gestational Diabetes 12.16.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 12.17. U.K. Diabetes Drugs Market Forecast, By Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Retail Pharmacies 12.17.3. Online Pharmacies 12.18. France Diabetes Drugs Market Forecast, By Treatment Type 12.18.1. Glucagon-like peptide-1 (GLP-1) agonist 12.18.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 12.18.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 12.18.4. Insulin 12.18.5. Exenatide 12.18.6. Liragultide 12.18.7. Pramlintide 12.18.8. Biguanides 12.18.9. Sulfonylureas 12.18.10. Meglitinides and D-Phenylalanine Derivatives 12.18.11. Thiazolidinediones 12.18.12. DPP-4 Inhibitors 12.18.13. Alpha-glucosidase Inhibitors 12.18.14. Bile Acid Sequestrants 12.18.15. Others (Combination Pills) 12.19. France Diabetes Drugs Market Forecast, By Disease Type 12.19.1. Type 1 Diabetes 12.19.2. Type 2 Diabetes 12.19.3. Gestational Diabetes 12.19.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 12.20. France Diabetes Drugs Market Forecast, By Distribution Channel 12.20.1. Hospital Pharmacies 12.20.2. Retail Pharmacies 12.20.3. Online Pharmacies 12.21. Italy Diabetes Drugs Market Forecast, By Treatment Type 12.21.1. Glucagon-like peptide-1 (GLP-1) agonist 12.21.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 12.21.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 12.21.4. Insulin 12.21.5. Exenatide 12.21.6. Liragultide 12.21.7. Pramlintide 12.21.8. Biguanides 12.21.9. Sulfonylureas 12.21.10. Meglitinides and D-Phenylalanine Derivatives 12.21.11. Thiazolidinediones 12.21.12. DPP-4 Inhibitors 12.21.13. Alpha-glucosidase Inhibitors 12.21.14. Bile Acid Sequestrants 12.21.15. Others (Combination Pills) 12.22. Italy Diabetes Drugs Market Forecast, By Disease Type 12.22.1. Type 1 Diabetes 12.22.2. Type 2 Diabetes 12.22.3. Gestational Diabetes 12.22.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 12.23. Italy Diabetes Drugs Market Forecast, By Distribution Channel 12.23.1. Hospital Pharmacies 12.23.2. Retail Pharmacies 12.23.3. Online Pharmacies 12.24. Spain Diabetes Drugs Market Forecast, By Treatment Type 12.24.1. Glucagon-like peptide-1 (GLP-1) agonist 12.24.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 12.24.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 12.24.4. Insulin 12.24.5. Exenatide 12.24.6. Liragultide 12.24.7. Pramlintide 12.24.8. Biguanides 12.24.9. Sulfonylureas 12.24.10. Meglitinides and D-Phenylalanine Derivatives 12.24.11. Thiazolidinediones 12.24.12. DPP-4 Inhibitors 12.24.13. Alpha-glucosidase Inhibitors 12.24.14. Bile Acid Sequestrants 12.24.15. Others (Combination Pills) 12.25. Spain Diabetes Drugs Market Forecast, By Disease Type 12.25.1. Type 1 Diabetes 12.25.2. Type 2 Diabetes 12.25.3. Gestational Diabetes 12.25.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 12.26. Spain Diabetes Drugs Market Forecast, By Distribution Channel 12.26.1. Hospital Pharmacies 12.26.2. Retail Pharmacies 12.26.3. Online Pharmacies 12.27. Rest of Europe Diabetes Drugs Market Forecast, By Treatment Type 12.27.1. Glucagon-like peptide-1 (GLP-1) agonist 12.27.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 12.27.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 12.27.4. Insulin 12.27.5. Exenatide 12.27.6. Liragultide 12.27.7. Pramlintide 12.27.8. Biguanides 12.27.9. Sulfonylureas 12.27.10. Meglitinides and D-Phenylalanine Derivatives 12.27.11. Thiazolidinediones 12.27.12. DPP-4 Inhibitors 12.27.13. Alpha-glucosidase Inhibitors 12.27.14. Bile Acid Sequestrants 12.27.15. Others (Combination Pills) 12.28. Rest of Europe Diabetes Drugs Market Forecast, By Disease Type 12.28.1. Type 1 Diabetes 12.28.2. Type 2 Diabetes 12.28.3. Gestational Diabetes 12.28.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 12.29. Rest of Europe Diabetes Drugs Market Forecast, By Distribution Channel 12.29.1. Hospital Pharmacies 12.29.2. Retail Pharmacies 12.29.3. Online Pharmacies 12.30. Europe Diabetes Drugs Market Attractiveness Analysis 12.30.1. By Treatment Type 12.30.2. By Disease Type 12.30.3. By Distribution Channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Diabetes Drugs Market Analysis 13.1. Key Findings 13.2. Asia Pacific Diabetes Drugs Market Overview 13.3. Asia Pacific Diabetes Drugs Market Value Share Analysis, By Treatment Type 13.4. Asia Pacific Diabetes Drugs Market Forecast, By Treatment Type 13.4.1. Glucagon-like peptide-1 (GLP-1) agonist 13.4.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 13.4.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 13.4.4. Insulin 13.4.5. Exenatide 13.4.6. Liragultide 13.4.7. Pramlintide 13.4.8. Biguanides 13.4.9. Sulfonylureas 13.4.10. Meglitinides and D-Phenylalanine Derivatives 13.4.11. Thiazolidinediones 13.4.12. DPP-4 Inhibitors 13.4.13. Alpha-glucosidase Inhibitors 13.4.14. Bile Acid Sequestrants 13.4.15. Others (Combination Pills) 13.5. Asia Pacific Diabetes Drugs Market Value Share Analysis, By Disease Type 13.6. Asia Pacific Diabetes Drugs Market Forecast, By Disease Type 13.6.1. Type 1 Diabetes 13.6.2. Type 2 Diabetes 13.6.3. Gestational Diabetes 13.6.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 13.7. Asia Pacific Diabetes Drugs Market Value Share Analysis, By Distribution Channel 13.8. Asia Pacific Diabetes Drugs Market Forecast, By Distribution Channel 13.8.1. Hospital Pharmacies 13.8.2. Retail Pharmacies 13.8.3. Online Pharmacies 13.9. Asia Pacific Diabetes Drugs Market Value Share Analysis, by Country 13.10. Asia Pacific Diabetes Drugs Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Diabetes Drugs Market Analysis, by Country 13.12. China Diabetes Drugs Market Forecast, By Treatment Type 13.12.1. Glucagon-like peptide-1 (GLP-1) agonist 13.12.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 13.12.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 13.12.4. Insulin 13.12.5. Exenatide 13.12.6. Liragultide 13.12.7. Pramlintide 13.12.8. Biguanides 13.12.9. Sulfonylureas 13.12.10. Meglitinides and D-Phenylalanine Derivatives 13.12.11. Thiazolidinediones 13.12.12. DPP-4 Inhibitors 13.12.13. Alpha-glucosidase Inhibitors 13.12.14. Bile Acid Sequestrants 13.12.15. Others (Combination Pills) 13.13. China Diabetes Drugs Market Forecast, By Disease Type 13.13.1. Type 1 Diabetes 13.13.2. Type 2 Diabetes 13.13.3. Gestational Diabetes 13.13.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 13.14. China Diabetes Drugs Market Forecast, By Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Retail Pharmacies 13.14.3. Online Pharmacies 13.15. India Diabetes Drugs Market Forecast, By Treatment Type 13.15.1. Glucagon-like peptide-1 (GLP-1) agonist 13.15.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 13.15.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 13.15.4. Insulin 13.15.5. Exenatide 13.15.6. Liragultide 13.15.7. Pramlintide 13.15.8. Biguanides 13.15.9. Sulfonylureas 13.15.10. Meglitinides and D-Phenylalanine Derivatives 13.15.11. Thiazolidinediones 13.15.12. DPP-4 Inhibitors 13.15.13. Alpha-glucosidase Inhibitors 13.15.14. Bile Acid Sequestrants 13.15.15. Others (Combination Pills) 13.16. India Diabetes Drugs Market Forecast, By Disease Type 13.16.1. Type 1 Diabetes 13.16.2. Type 2 Diabetes 13.16.3. Gestational Diabetes 13.16.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 13.17. India Diabetes Drugs Market Forecast, By Distribution Channel 13.17.1. Hospital Pharmacies 13.17.2. Retail Pharmacies 13.17.3. Online Pharmacies 13.18. Japan Diabetes Drugs Market Forecast, By Treatment Type 13.18.1. Glucagon-like peptide-1 (GLP-1) agonist 13.18.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 13.18.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 13.18.4. Insulin 13.18.5. Exenatide 13.18.6. Liragultide 13.18.7. Pramlintide 13.18.8. Biguanides 13.18.9. Sulfonylureas 13.18.10. Meglitinides and D-Phenylalanine Derivatives 13.18.11. Thiazolidinediones 13.18.12. DPP-4 Inhibitors 13.18.13. Alpha-glucosidase Inhibitors 13.18.14. Bile Acid Sequestrants 13.18.15. Others (Combination Pills) 13.19. Japan Diabetes Drugs Market Forecast, By Disease Type 13.19.1. Type 1 Diabetes 13.19.2. Type 2 Diabetes 13.19.3. Gestational Diabetes 13.19.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 13.20. Japan Diabetes Drugs Market Forecast, By Distribution Channel 13.20.1. Hospital Pharmacies 13.20.2. Retail Pharmacies 13.20.3. Online Pharmacies 13.21. ASEAN Diabetes Drugs Market Forecast, By Treatment Type 13.21.1. Glucagon-like peptide-1 (GLP-1) agonist 13.21.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 13.21.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 13.21.4. Insulin 13.21.5. Exenatide 13.21.6. Liragultide 13.21.7. Pramlintide 13.21.8. Biguanides 13.21.9. Sulfonylureas 13.21.10. Meglitinides and D-Phenylalanine Derivatives 13.21.11. Thiazolidinediones 13.21.12. DPP-4 Inhibitors 13.21.13. Alpha-glucosidase Inhibitors 13.21.14. Bile Acid Sequestrants 13.21.15. Others (Combination Pills) 13.22. ASEAN Diabetes Drugs Market Forecast, By Disease Type 13.22.1. Type 1 Diabetes 13.22.2. Type 2 Diabetes 13.22.3. Gestational Diabetes 13.22.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 13.23. ASEAN Diabetes Drugs Market Forecast, By Distribution Channel 13.23.1. Hospital Pharmacies 13.23.2. Retail Pharmacies 13.23.3. Online Pharmacies 13.24. Rest of Asia Pacific Diabetes Drugs Market Forecast, By Treatment Type 13.24.1. Glucagon-like peptide-1 (GLP-1) agonist 13.24.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 13.24.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 13.24.4. Insulin 13.24.5. Exenatide 13.24.6. Liragultide 13.24.7. Pramlintide 13.24.8. Biguanides 13.24.9. Sulfonylureas 13.24.10. Meglitinides and D-Phenylalanine Derivatives 13.24.11. Thiazolidinediones 13.24.12. DPP-4 Inhibitors 13.24.13. Alpha-glucosidase Inhibitors 13.24.14. Bile Acid Sequestrants 13.24.15. Others (Combination Pills) 13.25. Rest of Asia Pacific Diabetes Drugs Market Forecast, By Disease Type 13.25.1. Type 1 Diabetes 13.25.2. Type 2 Diabetes 13.25.3. Gestational Diabetes 13.25.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 13.26. Rest of Asia Pacific Diabetes Drugs Market Forecast, By Distribution Channel 13.26.1. Hospital Pharmacies 13.26.2. Retail Pharmacies 13.26.3. Online Pharmacies 13.27. Asia Pacific Diabetes Drugs Market Attractiveness Analysis 13.27.1. By Treatment Type 13.27.2. By Disease Type 13.27.3. By Distribution Channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Diabetes Drugs Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Diabetes Drugs Market Overview 14.3. Middle East & Africa Diabetes Drugs Market Value Share Analysis, By Treatment Type 14.4. Middle East & Africa Diabetes Drugs Market Forecast, By Treatment Type 14.4.1. Glucagon-like peptide-1 (GLP-1) agonist 14.4.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 14.4.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 14.4.4. Insulin 14.4.5. Exenatide 14.4.6. Liragultide 14.4.7. Pramlintide 14.4.8. Biguanides 14.4.9. Sulfonylureas 14.4.10. Meglitinides and D-Phenylalanine Derivatives 14.4.11. Thiazolidinediones 14.4.12. DPP-4 Inhibitors 14.4.13. Alpha-glucosidase Inhibitors 14.4.14. Bile Acid Sequestrants 14.4.15. Others (Combination Pills) 14.5. Middle East & Africa Diabetes Drugs Market Value Share Analysis, By Disease Type 14.6. Middle East & Africa Diabetes Drugs Market Forecast, By Disease Type 14.6.1. Type 1 Diabetes 14.6.2. Type 2 Diabetes 14.6.3. Gestational Diabetes 14.6.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 14.7. Middle East & Africa Diabetes Drugs Market Value Share Analysis, By Distribution Channel 14.8. Middle East & Africa Diabetes Drugs Market Forecast, By Distribution Channel 14.8.1. Hospital Pharmacies 14.8.2. Retail Pharmacies 14.8.3. Online Pharmacies 14.9. Middle East & Africa Diabetes Drugs Market Value Share Analysis, by Country 14.10. Middle East & Africa Diabetes Drugs Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Diabetes Drugs Market Analysis, by Country 14.12. GCC Diabetes Drugs Market Forecast, By Treatment Type 14.12.1. Glucagon-like peptide-1 (GLP-1) agonist 14.12.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 14.12.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 14.12.4. Insulin 14.12.5. Exenatide 14.12.6. Liragultide 14.12.7. Pramlintide 14.12.8. Biguanides 14.12.9. Sulfonylureas 14.12.10. Meglitinides and D-Phenylalanine Derivatives 14.12.11. Thiazolidinediones 14.12.12. DPP-4 Inhibitors 14.12.13. Alpha-glucosidase Inhibitors 14.12.14. Bile Acid Sequestrants 14.12.15. Others (Combination Pills) 14.13. GCC Diabetes Drugs Market Forecast, By Disease Type 14.13.1. Type 1 Diabetes 14.13.2. Type 2 Diabetes 14.13.3. Gestational Diabetes 14.13.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 14.14. GCC Diabetes Drugs Market Forecast, By Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Retail Pharmacies 14.14.3. Online Pharmacies 14.15. South Africa Diabetes Drugs Market Forecast, By Treatment Type 14.15.1. Glucagon-like peptide-1 (GLP-1) agonist 14.15.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 14.15.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 14.15.4. Insulin 14.15.5. Exenatide 14.15.6. Liragultide 14.15.7. Pramlintide 14.15.8. Biguanides 14.15.9. Sulfonylureas 14.15.10. Meglitinides and D-Phenylalanine Derivatives 14.15.11. Thiazolidinediones 14.15.12. DPP-4 Inhibitors 14.15.13. Alpha-glucosidase Inhibitors 14.15.14. Bile Acid Sequestrants 14.15.15. Others (Combination Pills) 14.16. South Africa Diabetes Drugs Market Forecast, By Disease Type 14.16.1. Type 1 Diabetes 14.16.2. Type 2 Diabetes 14.16.3. Gestational Diabetes 14.16.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 14.17. South Africa Diabetes Drugs Market Forecast, By Distribution Channel 14.17.1. Hospital Pharmacies 14.17.2. Retail Pharmacies 14.17.3. Online Pharmacies 14.18. Rest of Middle East & Africa Diabetes Drugs Market Forecast, By Treatment Type 14.18.1. Glucagon-like peptide-1 (GLP-1) agonist 14.18.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 14.18.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 14.18.4. Insulin 14.18.5. Exenatide 14.18.6. Liragultide 14.18.7. Pramlintide 14.18.8. Biguanides 14.18.9. Sulfonylureas 14.18.10. Meglitinides and D-Phenylalanine Derivatives 14.18.11. Thiazolidinediones 14.18.12. DPP-4 Inhibitors 14.18.13. Alpha-glucosidase Inhibitors 14.18.14. Bile Acid Sequestrants 14.18.15. Others (Combination Pills) 14.19. Rest of Middle East & Africa Diabetes Drugs Market Forecast, By Disease Type 14.19.1. Type 1 Diabetes 14.19.2. Type 2 Diabetes 14.19.3. Gestational Diabetes 14.19.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 14.20. Rest of Middle East & Africa Diabetes Drugs Market Forecast, By Distribution Channel 14.20.1. Hospital Pharmacies 14.20.2. Retail Pharmacies 14.20.3. Online Pharmacies 14.21. Middle East & Africa Diabetes Drugs Market Attractiveness Analysis 14.21.1. By Treatment Type 14.21.2. By Disease Type 14.21.3. By Distribution Channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Diabetes Drugs Market Analysis 15.1. Key Findings 15.2. South America Diabetes Drugs Market Overview 15.3. South America Diabetes Drugs Market Value Share Analysis, By Treatment Type 15.4. South America Diabetes Drugs Market Forecast, By Treatment Type 15.4.1. Glucagon-like peptide-1 (GLP-1) agonist 15.4.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 15.4.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 15.4.4. Insulin 15.4.5. Exenatide 15.4.6. Liragultide 15.4.7. Pramlintide 15.4.8. Biguanides 15.4.9. Sulfonylureas 15.4.10. Meglitinides and D-Phenylalanine Derivatives 15.4.11. Thiazolidinediones 15.4.12. DPP-4 Inhibitors 15.4.13. Alpha-glucosidase Inhibitors 15.4.14. Bile Acid Sequestrants 15.4.15. Others (Combination Pills) 15.5. South America Diabetes Drugs Market Value Share Analysis, By Disease Type 15.6. South America Diabetes Drugs Market Forecast, By Disease Type 15.6.1. Type 1 Diabetes 15.6.2. Type 2 Diabetes 15.6.3. Gestational Diabetes 15.6.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 15.7. South America Diabetes Drugs Market Value Share Analysis, By Distribution Channel 15.8. South America Diabetes Drugs Market Forecast, By Distribution Channel 15.8.1. Hospital Pharmacies 15.8.2. Retail Pharmacies 15.8.3. Online Pharmacies 15.9. South America Diabetes Drugs Market Value Share Analysis, by Country 15.10. South America Diabetes Drugs Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Diabetes Drugs Market Analysis, by Country 15.12. Brazil Diabetes Drugs Market Forecast, By Treatment Type 15.12.1. Glucagon-like peptide-1 (GLP-1) agonist 15.12.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 15.12.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 15.12.4. Insulin 15.12.5. Exenatide 15.12.6. Liragultide 15.12.7. Pramlintide 15.12.8. Biguanides 15.12.9. Sulfonylureas 15.12.10. Meglitinides and D-Phenylalanine Derivatives 15.12.11. Thiazolidinediones 15.12.12. DPP-4 Inhibitors 15.12.13. Alpha-glucosidase Inhibitors 15.12.14. Bile Acid Sequestrants 15.12.15. Others (Combination Pills) 15.13. Brazil Diabetes Drugs Market Forecast, By Disease Type 15.13.1. Type 1 Diabetes 15.13.2. Type 2 Diabetes 15.13.3. Gestational Diabetes 15.13.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 15.14. Brazil Diabetes Drugs Market Forecast, By Distribution Channel 15.14.1. Hospital Pharmacies 15.14.2. Retail Pharmacies 15.14.3. Online Pharmacies 15.15. Mexico Diabetes Drugs Market Forecast, By Treatment Type 15.15.1. Glucagon-like peptide-1 (GLP-1) agonist 15.15.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 15.15.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 15.15.4. Insulin 15.15.5. Exenatide 15.15.6. Liragultide 15.15.7. Pramlintide 15.15.8. Biguanides 15.15.9. Sulfonylureas 15.15.10. Meglitinides and D-Phenylalanine Derivatives 15.15.11. Thiazolidinediones 15.15.12. DPP-4 Inhibitors 15.15.13. Alpha-glucosidase Inhibitors 15.15.14. Bile Acid Sequestrants 15.15.15. Others (Combination Pills) 15.16. Mexico Diabetes Drugs Market Forecast, By Disease Type 15.16.1. Type 1 Diabetes 15.16.2. Type 2 Diabetes 15.16.3. Gestational Diabetes 15.16.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 15.17. Mexico Diabetes Drugs Market Forecast, By Distribution Channel 15.17.1. Hospital Pharmacies 15.17.2. Retail Pharmacies 15.17.3. Online Pharmacies 15.18. Rest of South America Diabetes Drugs Market Forecast, By Treatment Type 15.18.1. Glucagon-like peptide-1 (GLP-1) agonist 15.18.2. Dipeptidyl-peptidase-4 (DPP-4) inhibitors 15.18.3. Sodium glucose co-transporter 2 (SGLT2) inhibitors 15.18.4. Insulin 15.18.5. Exenatide 15.18.6. Liragultide 15.18.7. Pramlintide 15.18.8. Biguanides 15.18.9. Sulfonylureas 15.18.10. Meglitinides and D-Phenylalanine Derivatives 15.18.11. Thiazolidinediones 15.18.12. DPP-4 Inhibitors 15.18.13. Alpha-glucosidase Inhibitors 15.18.14. Bile Acid Sequestrants 15.18.15. Others (Combination Pills) 15.19. Rest of South America Diabetes Drugs Market Forecast, By Disease Type 15.19.1. Type 1 Diabetes 15.19.2. Type 2 Diabetes 15.19.3. Gestational Diabetes 15.19.4. Impaired Glucose Tolerance and Impaired Fasting Glycaemia 15.20. Rest of South America Diabetes Drugs Market Forecast, By Distribution Channel 15.20.1. Hospital Pharmacies 15.20.2. Retail Pharmacies 15.20.3. Online Pharmacies 15.21. South America Diabetes Drugs Market Attractiveness Analysis 15.21.1. By Treatment Type 15.21.2. By Disease Type 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Disease Types and R&D investment 16.2.2. New Treatment Center Launches and Treatment Center Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Disease Types 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Nordisk A/S 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Treatment Center Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Merck & Co., Inc. 16.3.3. Novartis AG 16.3.4. Boehringer Ingelheim GmbH 16.3.5. Sanofi 16.3.6. Bayer AG 16.3.7. Johnson & Johnson 16.3.8. Eli Lilly and Company 16.3.9. Takeda Pharmaceutical Company Limited. 16.3.10. Abbott laboratories 16.3.11. Biocon ltd. 16.3.12. Bristol-Myers Squibb 16.3.13. Dr. Reddy's laboratories ltd. 16.3.14. Glaxosmithkline 16.3.15. Lupin ltd. 16.3.16. Piramal healthcare ltd. 16.3.17. Ranbaxy laboratories ltd. 16.3.18. AstraZeneca 16.3.19. Sunpharma 16.3.20. Pfizer 16.3.21. Daiichi Sankyo 16.3.22. Akros Pharma 16.3.23. Amgen 16.3.24. Adocia 16.3.25. Peptron 17. Primary Key Insights

About This Report

Report ID 37170
Category Healthcare
Published Date June 2022
Updated Date
Contact Us